Establishing organoids from metastatic pancreatic cancer patients, the OPT-I study
Recruiting
- Conditions
- pancreatic adenocarcinomapancreatic cancer10027476
- Registration Number
- NL-OMON55389
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
- Patients older than 18 years
- Diagnosed with locally advanced pancreatic cancer or metastatic pancreatic
cancer
- Able to understand the information given
- WHO 0-2
Exclusion Criteria
- Unfit for biopsies & blood analyses in palliative chemotherapy studies
- Not able to give informed consent (language, intellectual capacities, etc.)
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The development of organoids from biopsies of metastases or primary tumour<br /><br>tissue of pancreatic cancer. The response of the organoids will be assessed for<br /><br>correlation with clinical response. </p><br>
- Secondary Outcome Measures
Name Time Method <p>The expression of bio markers in organoid, organotypic and xenograft models<br /><br>will be investigated. DNA/RNA profiles will be correlated to clinical and<br /><br>pathological characteristics such as therapy response, survival and TNM<br /><br>classification. </p><br>